Peetz Christopher's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Jan 27, 2026
- Accession no.
- 0001614740-26-000003
- Filed
- Jan 27, 2026
- Trade date
- Jan 23-26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $657.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Peetz ChristopherCIK 0001614740 | Director, Officer (CHIEF EXECUTIVE OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Common Stock | MOption exerciseAcquired | +12,500 | – | – | 176,233 | Direct | |
| Jan 26, 2026 | Common Stock | SSaleDisposed | −6,831 | $96.19 | −$657,073.89 | 169,402 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Common Stock | MOption exerciseDisposed | −12,500 | $0.00 | $0 | 12,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.